arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Geron Corporation

GERN Health Care Biotechnology: Pharmaceutical Preparations
$1.12
▼ -3.5% Today
as of Oct 23, 16:49 ET
Last 30 days -18.25% Sep 14 → Oct 23
$1.10 $1.17 $1.25 $1.32 $1.39 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$1.15
High
$1.15
Low
$1.08
Volume
$11M
Avg Vol
$12M
Mkt Cap
$771M
P/E (TTM)
—
Beta
—
52w High
$2.01
52w Low
$1.04
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 7 items

Oct 21 · 12:00 PR GlobeNewswire
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
Oct 19 · 20:01 PR GlobeNewswire
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 12 · 12:03 PR GlobeNewswire
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
▸ Show all 7 press releases & news Free account →

GERN earnings at a glance

Geron Corporation (GERN) is scheduled to report earnings on Wednesday, November 4, 2026 — in 11 days. Analysts expect earnings per share of -$0.01, compared with -$0.03 in the same quarter last year (+67%). The options market is pricing a move of about ±50.0% after the report, a range of roughly $0.56 to $1.68 from today's $1.12. Over its last 6 reports the stock rose the next day 1 time and fell 5, moving ±6.9% on average; after the most recent report on Aug 5, 2026 it moved -3.7%. That means options currently expect more movement than GERN has typically delivered. GERN beat the consensus EPS estimate in 3 of its last 6 reported quarters. Implied volatility is currently 379%. The share price of $1.12 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.04
$2.01
8% of range
Avg surprise (last 6)
+4.2%
Avg reaction (last 6)
-1.6%
17% positive
Latest IV / EM
379%
EM ±50.0% · $1 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.60$-0.33$-0.06$0.22$0.49 Actual $-0.07Actual $-0.09Actual $-0.08Actual $-0.09Actual $-0.10Actual $-0.04Actual $-0.03Est $-0.04Actual $-0.02Est $-0.03Actual $-0.03Est $-0.03Actual $-0.03Est $-0.03Actual $-0.01Est $-0.03Actual $-0.02Est $-0.01 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-26M$-5M$17M$39M$60M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed Aug 5, 2026Jun/2026 $-0.02 $-0.01 -100.0% +50.0% -3.7% earnings
Wed May 6, 2026Mar/2026 $-0.01 $-0.03 +66.7% +66.7% -4.2% earnings
Wed Feb 25, 20268K 2026-02-25 $-0.03 $-0.03 0.0% — -11.8% earnings
Wed Nov 5, 2025Sep/2025 $-0.03 $-0.03 0.0% — -5.2% earnings
Wed Aug 6, 2025Jun/2025 $-0.02 $-0.03 +33.3% — +15.8% earnings
Wed May 7, 2025Mar/2025 $-0.03 $-0.04 +25.0% — -0.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.04 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.10 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.09 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.08 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.09 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.07 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER -$0.01-$0.03 +66.7%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$57M$52M—$47M$49M$40M—$28M
Cost of revenue————————
Gross profit————————
Operating income$-12M$158,000—$-14M$-12M$-17M—$-28M
Net income$-17M$-4M—$-18M$-16M$-20M—$-26M
EPS (diluted)$-0.02$-0.01—$-0.03$-0.02$-0.03—$-0.04

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$63M$69M$78M$78M$78M$84M$79M$60M
Inventory$124M$133M$117M$95M$69M$56M$39M$20M
Total current assets$486M$499M$520M$522M$506M$496M$491M$398M
Total assets$519M$534M$571M$567M$555M$562M$594M$445M
Long-term debt$120M$120M$120M$119M$119M$119M$118M$12M
Total liabilities$300M$305M$345M—————
Total equity$219M$229M$226M$249M$260M$268M$280M$292M

Implied volatility — last 90 days

54%244%435%625%816% Jun 07 — IV 339% · EM ±47.0%Jun 08 — IV 201% · EM ±26.5%Jun 09 — IV 321% · EM ±40.2%Jun 10 — IV 233% · EM ±27.5%Jun 12 — IV 298% · EM ±30.4%Jun 15 — IV 414% · EM ±30.0%Jun 24 — IV 54% · EM ±10.9%Jun 29 — IV 64% · EM ±11.4%Jun 30 — IV 181% · EM ±31.2%Jul 07 — IV 77% · EM ±10.2%Jul 08 — IV 77% · EM ±9.6%Jul 09 — IV 122% · EM ±14.4%Jul 10 — IV 90% · EM ±10.0%Jul 13 — IV 126% · EM ±10.6%Jul 14 — IV 144% · EM ±10.4%Jul 20 — IV 96% · EM ±22.6%Jul 21 — IV 82% · EM ±19.1%Jul 22 — IV 101% · EM ±23.1%Jul 23 — IV 107% · EM ±24.1%Jul 24 — IV 96% · EM ±21.1%Jul 27 — IV 96% · EM ±20.1%Jul 28 — IV 101% · EM ±20.7%Jul 29 — IV 113% · EM ±22.7%Jul 30 — IV 114% · EM ±22.4%Jul 31 — IV 141% · EM ±27.0%Aug 03 — IV 121% · EM ±21.5%Aug 04 — IV 220% · EM ±37.9%Aug 05 — IV 94% · EM ±15.6%Aug 06 — IV 88% · EM ±14.2%Aug 07 — IV 98% · EM ±15.3%Aug 10 — IV 123% · EM ±17.0%Aug 11 — IV 138% · EM ±18.2%Aug 12 — IV 153% · EM ±19.2%Aug 13 — IV 136% · EM ±16.1%Aug 14 — IV 123% · EM ±13.6%Aug 17 — IV 117% · EM ±9.8%Aug 24 — IV 79% · EM ±16.4%Aug 25 — IV 71% · EM ±14.5%Aug 26 — IV 82% · EM ±16.3%Aug 27 — IV 75% · EM ±14.7%Aug 28 — IV 87% · EM ±16.6%Aug 31 — IV 66% · EM ±11.7%Sep 01 — IV 78% · EM ±13.5%Sep 02 — IV 95% · EM ±15.9%Sep 03 — IV 61% · EM ±9.9%Sep 04 — IV 92% · EM ±14.3%Sep 07 — IV 103% · EM ±14.3%Sep 08 — IV 75% · EM ±9.9%Sep 09 — IV 142% · EM ±17.7%Sep 10 — IV 93% · EM ±10.9%Sep 11 — IV 200% · EM ±22.1%Sep 14 — IV 175% · EM ±14.6%Sep 15 — IV 314% · EM ±22.7%Sep 16 — IV 591% · EM ±34.9%Sep 17 — IV 816% · EM ±34.1%Sep 21 — IV 201% · EM ±42.1%Sep 22 — IV 280% · EM ±57.3%Sep 23 — IV 161% · EM ±32.3%Sep 24 — IV 182% · EM ±35.7%Sep 25 — IV 228% · EM ±43.7%Oct 06 — IV 379% · EM ±50.0%

Sector peers

WVE
Wave Life Sciences, Inc.
$765M $3.18-5.6%
LXRX
Lexicon Pharmaceuticals, Inc.
$783M $1.42-9.0%
DSGN
Design Therapeutics, Inc.
$732M $10.24-4.6%
ESPR
Esperion Therapeutics, Inc.
$819M $3.18
MDXG
MiMedx Group, Inc
$672M $3.91+4.5%
HELP
Helus Pharma Inc.
$870M $10.19-5.5%

GERN earnings FAQ

When is GERN's next earnings date?

Geron Corporation is expected to report on November 4, 2026.

What is GERN's expected move for earnings?

Options currently price a move of about ±50.0%, or $0.56 per share either way from $1.12.

How does GERN stock usually react to earnings?

Across the last 6 reports the average next-day move was ±6.9%, up 1 times and down 5 times.

What EPS are analysts expecting from Geron Corporation?

The consensus estimate is -$0.01 per share, versus -$0.03 a year ago.

What is GERN's implied volatility?

GERN's at-the-money implied volatility is about 379% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in